


Gilvetmab: An Innovative Option for Treating Cancer



Gilvetmab is the first and only immune checkpoint inhibitor developed for the treatment of cancer in dogs

Gilvetmab is a caninized monoclonal antibody used to treat mast cell tumors (MCTs) and melanomas and offers hope even for patients with metastatic disease.



Ideal systemic treatment option labeled for dogs with stage I, II, and III MCTs, as well as dogs with stage II and III melanomas




Targeted to disrupt the interaction between PD-L1/L2 and the PD-1 receptor, preventing suppression of T lymphocytes by the tumor, and enhancing the ability of the immune system to destroy cancer cells¹

* Objective response=46%.

† Objective response=20%.

Quality of life without compromise in the majority of dogs treated



77.4% of veterinarians reported a quality of life performance score of 0 or 1^{2,3†}



A field study demonstrated that gilvetmab is **well tolerated** in dogs with MCTs or melanomas⁴



Adverse reactions reported were **generally transient** and included mainly lethargy and inappetence/GI upset[‡]

*Unlike chemotherapy, **no special handling is required** to ensure the safety of veterinary staff and pet owners.*

Want to stay informed about gilvetmab?

Sign up to receive product information and updates on availability.



* Based on pet owner assessment during treatment.

† 0=uncompromised quality of life. 1=demonstrating clinical signs directly related to disease without compromised quality of life.

‡ Refer to product insert for more information.

INDICATION

This product contains gilvetmab, a caninized monoclonal antibody against canine programmed cell death receptor-1. For the treatment of dogs with mast cell tumors or melanomas. This product has demonstrated a reasonable expectation of efficacy and a preliminary safety profile in reducing the solid tumor burden in dogs with stage I, II, and III mast cell tumors or dogs with stage II and III melanomas. This product license is Conditional; safety, efficacy, and potency have not been fully evaluated. For more information regarding safety, see productdata.aphis.usda.gov.

References: 1. Yearley JH, Gibson C, Yu N, et al. PD-L2 expression in human tumors: Relevance to Anti-PD-1 therapy in cancer. *Clin Cancer Res.* 2017;23(12)3158-3167. doi:10.1158/1078-0432.CCR-16-1761 2. Data on file. Merck Animal Health. 3. Lynch S., K. Savary-Bataille, B. Leeuw, D.J. Argyle. (2010) Development of a questionnaire assessing health related quality-of-life in dogs and cats with cancer. *Veterinary and Comparative Oncology* (9) 172-182 4. Gilvetmab product insert. Madison, NJ: Merck Animal Health; 2022.